Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Restructuring Costs (2020 - 2024)

Aytu Biopharma (AYTU) has disclosed Restructuring Costs for 3 consecutive years, with $1.3 million as the latest value for Q4 2024.

  • On a quarterly basis, Restructuring Costs changed N/A to $1.3 million in Q4 2024 year-over-year; TTM through Sep 2025 was $1.3 million, a 55.2% decrease, with the full-year FY2025 number at $2.1 million, down 2.55% from a year prior.
  • Restructuring Costs was $1.3 million for Q4 2024 at Aytu Biopharma, up from $784000.0 in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $2.9 million in Q1 2021 to a low of $70000.0 in Q2 2021.
  • A 3-year average of $1.1 million and a median of $814277.0 in 2020 define the central range for Restructuring Costs.
  • Biggest YoY gain for Restructuring Costs was 91.4% in 2021; the steepest drop was 91.4% in 2021.
  • Aytu Biopharma's Restructuring Costs stood at $814277.0 in 2020, then tumbled by 91.4% to $70000.0 in 2021, then skyrocketed by 1781.43% to $1.3 million in 2024.
  • Per Business Quant, the three most recent readings for AYTU's Restructuring Costs are $1.3 million (Q4 2024), $784000.0 (Q3 2024), and $1.9 million (Q2 2024).